Quick Takeaways
- ADPT - Adaptive Biotechnologies Corp has 22 insiders with reported activity on this page.
- Net insider value flow over the last year: -$68,089,533.
- Recent transaction rows are available for direct filing-level review.
Insider Transactions Reported by 22 Insiders of Adaptive Biotechnologies Corp
- Symbol
- ADPT on Nasdaq
- Location
- Seattle, WA
What Changed
- Buy value: ; sell value: $68,089,533.
- Net share flow: -4,463,767.
Why This Matters
- This page gives a plain-language issuer insider context before you inspect transaction-level evidence.
- Use the filing links below to verify timestamps, codes, and ownership impacts directly from SEC forms.
Source Evidence
Filed on Form 4
See Original Filing
Issuer insider activity is sourced from SEC Forms 3, 4, and 5.
Insider trading overview
Last 12 monthsNet insider flow leans to selling over the last 12 months. Net value: -$68,089,533.
Buys
$0
Shares: 0
Insiders: 0
Sells
$68,089,533
Shares: 4,463,767
Insiders: 9
Net
-$68,089,533
Shares: -4,463,767
Insiders: -9
| Window (months) | Buy shares | Sell shares | Buy $ | Sell $ | Net $ |
|---|---|---|---|---|---|
| 0-3 | 0 | 2,847,448 | $0 | $40,300,823 | -$40,300,823 |
| 3-6 | 0 | 1,513,196 | $0 | $26,291,033 | -$26,291,033 |
| 6-9 | 0 | 99,265 | $0 | $1,463,380 | -$1,463,380 |
| 9-12 | 0 | 3,858 | $0 | $34,298 | -$34,298 |
Adaptive Biotechnologies Corp executives and other stock owners filed with the SEC include:
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Chad M. Robins | CEO and Chairman, Director | $33,122,068 | -$24,919,160 | -43% | Filing P/S | 06 Apr 2026 |
| Harlan S. Robins | Chief Scientific Officer | $22,454,061 | -$8,518,453 | -28% | Filing P/S | 08 Apr 2026 |
| Susan Bobulsky | Chief Commercial Officer, MRD | $5,633,796 | -$544,421 | -8.8% | Filing P/S | 11 Mar 2026 |
| Julie Rubinstein | President and COO | $5,376,122 | -$13,371,111 | -71% | Filing P/S | 27 Apr 2026 |
| Francis Lo | Chief People Officer | $4,120,990 | -$4,656,869 | -53% | Mixed | 08 Apr 2026 |
| Peter M. Neupert | Director | $3,811,395 | Mixed | 04 Mar 2026 | ||
| Sharon Benzeno | Chief Commercial Ofc Imm Med | $3,592,130 | -$11,187,469 | -76% | Filing P/S | 11 Mar 2026 |
| Kyle Piskel | Chief Financial Officer | $3,422,092 | -$3,575,358 | -51% | Filing P/S | 11 Mar 2026 |
| Tycho Peterson | Chief Financial Officer | $1,828,542 | Filing P/S | 04 Mar 2024 | ||
| Katey Einterz Owen | Director | $1,399,708 | Mixed | 04 Mar 2026 | ||
| Robert Hershberg | Director | $988,823 | -$367,488 | -27% | Mixed | 04 Mar 2026 |
| Nitin Sood | Chief Commercial Officer, MRD | $887,157 | Mixed | 07 Aug 2023 | ||
| R. Mark Adams | Chief Operating Officer | $724,241 | Mixed | 10 Apr 2023 | ||
| Stacy L. Taylor | SVP and General Counsel | $626,780 | Filing P/S | 22 Aug 2024 | ||
| Michael J. Pellini | Director | $553,339 | Mixed | 04 Mar 2025 | ||
| Michelle Renee Griffin | Director | $217,343 | -$949,204 | -81% | Filing P/S | 11 Mar 2026 |
| Henning Thorsen | SVP, Commercial Operations | $120,022 | Mixed | 17 May 2021 | ||
| Leslie Trigg | Director | $106,996 | Mixed | 06 Mar 2023 | ||
| Conroy Kevin T. | Director | $94,858 | Mixed | 06 Mar 2023 | ||
| Chad M. Cohen | Chief Financial Officer | $89,225 | Mixed | 22 Dec 2021 | ||
| Lance Baldo | Chief Medical Officer | $70,916 | Mixed | 08 Mar 2022 | ||
| Jyoti Palaniappan | SVP, Diagnostics, T-Detect | $37,823 | Mixed | 19 Jul 2021 |
Top shareholders of Adaptive Biotechnologies Corp (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| VIKING GLOBAL INVESTORS LP |
13F
|
Company |
20%
|
29,993,708
|
$487,097,818 | — | 31 Dec 2025 | |
| BlackRock, Inc. |
13F
13D/G
|
Company |
7.9%
from 13D/G
|
13,333,559
|
$216,536,989 | — | 31 Dec 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
7.4%
|
11,282,152
|
$183,222,148 | — | 31 Dec 2025 | |
| Rubric Capital Management LP |
13D/G
|
— |
4.1%
|
6,256,847
|
$72,889,139 | $0 | 30 Jun 2025 | |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13F
|
Company |
2.9%
|
4,387,361
|
$71,252,000 | — | 31 Dec 2025 | |
| WESTFIELD CAPITAL MANAGEMENT CO LP |
13F
|
Company |
2.7%
|
4,060,481
|
$65,942,211 | — | 31 Dec 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
2.3%
|
3,511,855
|
$57,040,977 | — | 31 Dec 2025 | |
| Amova Asset Management Americas, Inc. |
13D/G
13F
|
Nikko Asset Management Americas, Inc. · Company |
4.6%
|
6,833,137
|
$53,981,782 | $0 | 31 Dec 2024 | |
| Sumitomo Mitsui Trust Group, Inc. |
13D/G
13F
|
Company |
4.6%
|
6,833,137
|
$53,981,782 | $0 | 31 Dec 2024 | |
| STATE STREET CORP |
13F
|
Company |
2.1%
|
3,181,644
|
$51,669,899 | — | 31 Dec 2025 | |
| Invesco Ltd. |
13F
|
Company |
2%
|
3,107,653
|
$50,468,285 | — | 31 Dec 2025 | |
| LORD, ABBETT & CO. LLC |
13F
|
Company |
2%
|
3,080,759
|
$50,032,000 | — | 31 Dec 2025 | |
| INTEGRATED CORE STRATEGIES (US) LLC |
13D/G
|
Millennium Management LLC |
4.3%
|
6,292,634
|
$49,711,809 | $0 | 31 Dec 2024 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
1.9%
|
2,902,269
|
$47,132,848 | — | 31 Dec 2025 | |
| DRIEHAUS CAPITAL MANAGEMENT LLC |
13F
|
Company |
1.8%
|
2,760,387
|
$44,828,685 | — | 31 Dec 2025 | |
| JENNISON ASSOCIATES LLC |
13F
|
Company |
1.8%
|
2,674,668
|
$43,436,609 | — | 31 Dec 2025 | |
| AMERIPRISE FINANCIAL INC |
13F
|
Company |
1.7%
|
2,590,984
|
$42,077,600 | — | 31 Dec 2025 | |
| ARK Investment Management LLC |
13D/G
13F
|
Company |
2.9%
|
4,398,669
|
$40,863,635 | -$15,506,311 | 31 May 2025 | |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP |
13F
|
Company |
1.6%
|
2,422,089
|
$39,334,725 | — | 31 Dec 2025 | |
| FRED ALGER MANAGEMENT, LLC |
13F
|
Company |
1.5%
|
2,245,418
|
$36,465,588 | — | 31 Dec 2025 | |
| WELLINGTON MANAGEMENT GROUP LLP |
13F
|
Company |
1.4%
|
2,165,327
|
$35,164,911 | — | 31 Dec 2025 | |
| Chad M. Robins |
3/4/5
|
CEO and Chairman, Director |
1.4%
|
2,180,518
|
$33,122,068 | -$24,919,160 | 06 Apr 2026 | |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. |
13F
|
Company |
1.3%
|
1,940,376
|
$31,512,000 | — | 31 Dec 2025 | |
| D. E. Shaw & Co., Inc. |
13F
|
Company |
1.3%
|
1,902,685
|
$30,899,604 | — | 31 Dec 2025 | |
| Aristotle Atlantic Partners, LLC |
13F
|
Company |
1.2%
|
1,842,444
|
$29,921,291 | — | 31 Dec 2025 | |
| Blue Water Life Science Advisors, LP |
13F
|
Company |
1.2%
|
1,765,145
|
$28,665,955 | — | 31 Dec 2025 | |
| DEUTSCHE BANK AG\ |
13F
|
Company |
1.1%
|
1,734,465
|
$28,167,711 | — | 31 Dec 2025 | |
| PBU - The Pension Fund of Early Childhood & Youth Educators |
13F
|
Company |
1.1%
|
1,650,303
|
$26,800,921 | — | 31 Dec 2025 | |
| PRINCIPAL FINANCIAL GROUP INC |
13F
|
Company |
1%
|
1,552,509
|
$25,212,746 | — | 31 Dec 2025 | |
| DIMENSIONAL FUND ADVISORS LP |
13F
|
Company |
0.91%
|
1,382,924
|
$22,459,871 | — | 31 Dec 2025 | |
| Harlan S. Robins |
3/4/5
|
Chief Scientific Officer |
1%
|
1,512,058
|
$22,454,061 | -$8,518,453 | 08 Apr 2026 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.77%
|
1,173,535
|
$19,058,208 | — | 31 Dec 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.77%
|
1,172,794
|
$19,046,174 | — | 31 Dec 2025 | |
| MORGAN STANLEY |
13F
|
Company |
0.76%
|
1,149,082
|
$18,661,111 | — | 31 Dec 2025 | |
| Aberdeen Group plc |
13F
|
Company |
0.69%
|
1,046,510
|
$16,995,322 | — | 31 Dec 2025 | |
| NEXT CENTURY GROWTH INVESTORS LLC |
13F
|
Company |
0.62%
|
943,597
|
$15,324,015 | — | 31 Dec 2025 | |
| MASSACHUSETTS FINANCIAL SERVICES CO /MA/ |
13F
|
Company |
0.61%
|
922,501
|
$14,981,416 | — | 31 Dec 2025 | |
| Qube Research & Technologies Ltd |
13F
|
Company |
0.6%
|
914,160
|
$14,845,958 | — | 31 Dec 2025 | |
| KENNEDY CAPITAL MANAGEMENT LLC |
13F
|
Company |
0.59%
|
900,231
|
$14,619,751 | — | 31 Dec 2025 | |
| ALGERT GLOBAL LLC |
13F
|
Company |
0.58%
|
884,371
|
$14,362,000 | — | 31 Dec 2025 | |
| Catalio Capital Management, LP |
13F
|
Company |
0.54%
|
821,195
|
$13,336,207 | — | 31 Dec 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.53%
|
806,272
|
$13,093,856 | — | 31 Dec 2025 | |
| Nuveen, LLC |
13F
|
Company |
0.52%
|
786,647
|
$12,775,148 | — | 31 Dec 2025 | |
| OBERWEIS ASSET MANAGEMENT INC/ |
13F
|
Company |
0.49%
|
744,500
|
$12,090,680 | — | 31 Dec 2025 | |
| ESSEX INVESTMENT MANAGEMENT CO LLC |
13F
|
Company |
0.41%
|
624,217
|
$10,137,284 | — | 31 Dec 2025 | |
| Hillsdale Investment Management Inc. |
13F
|
Company |
0.41%
|
616,950
|
$10,019,267 | — | 31 Dec 2025 | |
| STEMPOINT CAPITAL LP |
13F
|
Company |
0.4%
|
606,825
|
$9,854,838 | — | 31 Dec 2025 | |
| Rhenman & Partners Asset Management AB |
13F
|
Company |
0.4%
|
605,000
|
$9,825,200 | — | 31 Dec 2025 | |
| Connor, Clark & Lunn Investment Management Ltd. |
13F
|
Company |
0.39%
|
591,324
|
$9,603,102 | — | 31 Dec 2025 | |
| TUDOR INVESTMENT CORP ET AL |
13F
|
Company |
0.36%
|
554,037
|
$8,997,561 | — | 31 Dec 2025 |
Recent Insider Transactions by Companies or Individuals for Adaptive Biotechnologies Corp
Showing up to 300 most recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Julie Rubinstein | ADPT | Common Stock | Sale | -4.8% | $270,897 | $14.23 | -19,037 | 377,802 | 27 Apr 2026 | Direct |
| Julie Rubinstein | ADPT | Common Stock | Options Exercise | 3.85% | 14,707 | 396,839 | 27 Apr 2026 | Direct | ||
| Julie Rubinstein | ADPT | Stock Option (right to buy) | Options Exercise | -24.3% | -14,707 | 45,731 | 27 Apr 2026 | Direct | ||
| Julie Rubinstein | ADPT | Common Stock | Sale | -4.75% | $267,221 | $14.02 | -19,060 | 382,132 | 24 Apr 2026 | Direct |
| Julie Rubinstein | ADPT | Common Stock | Options Exercise | 3.81% | 14,722 | 401,192 | 24 Apr 2026 | Direct | ||
| Julie Rubinstein | ADPT | Stock Option (right to buy) | Options Exercise | -19.6% | -14,722 | 60,438 | 24 Apr 2026 | Direct | ||
| Julie Rubinstein | ADPT | Common Stock | Sale | -4.7% | $261,884 | $13.74 | -19,060 | 386,470 | 23 Apr 2026 | Direct |
| Julie Rubinstein | ADPT | Common Stock | Options Exercise | 3.77% | 14,722 | 405,530 | 23 Apr 2026 | Direct | ||
| Julie Rubinstein | ADPT | Stock Option (right to buy) | Options Exercise | -16.4% | -14,722 | 75,160 | 23 Apr 2026 | Direct | ||
| Julie Rubinstein | ADPT | Common Stock | Sale | -4.65% | $269,318 | $14.13 | -19,060 | 390,808 | 22 Apr 2026 | Direct |
| Julie Rubinstein | ADPT | Common Stock | Options Exercise | 3.73% | 14,722 | 409,868 | 22 Apr 2026 | Direct | ||
| Julie Rubinstein | ADPT | Stock Option (right to buy) | Options Exercise | -14.1% | -14,722 | 89,882 | 22 Apr 2026 | Direct | ||
| Julie Rubinstein | ADPT | Common Stock | Sale | -7.26% | $453,595 | $14.66 | -30,941 | 395,146 | 21 Apr 2026 | Direct |
| Julie Rubinstein | ADPT | Common Stock | Options Exercise | 6.66% | 26,603 | 426,087 | 21 Apr 2026 | Direct | ||
| Julie Rubinstein | ADPT | Stock Option (right to buy) | Options Exercise | -20.3% | -26,603 | 104,604 | 21 Apr 2026 | Direct | ||
| Julie Rubinstein | ADPT | Common Stock | Sale | -4.55% | $277,323 | $14.55 | -19,060 | 399,484 | 20 Apr 2026 | Direct |
| Julie Rubinstein | ADPT | Common Stock | Options Exercise | 3.65% | 14,722 | 418,544 | 20 Apr 2026 | Direct | ||
| Julie Rubinstein | ADPT | Stock Option (right to buy) | Options Exercise | -11% | -14,722 | 119,326 | 20 Apr 2026 | Direct | ||
| Julie Rubinstein | ADPT | Common Stock | Sale | -4.51% | $277,704 | $14.57 | -19,060 | 403,822 | 17 Apr 2026 | Direct |
| Julie Rubinstein | ADPT | Common Stock | Options Exercise | 3.61% | 14,722 | 422,882 | 17 Apr 2026 | Direct | ||
| Julie Rubinstein | ADPT | Stock Option (right to buy) | Options Exercise | -9.9% | -14,722 | 134,048 | 17 Apr 2026 | Direct | ||
| Julie Rubinstein | ADPT | Common Stock | Sale | -4.46% | $270,271 | $14.18 | -19,060 | 408,160 | 16 Apr 2026 | Direct |
| Julie Rubinstein | ADPT | Common Stock | Options Exercise | 3.57% | 14,722 | 427,220 | 16 Apr 2026 | Direct | ||
| Julie Rubinstein | ADPT | Stock Option (right to buy) | Options Exercise | -9% | -14,722 | 148,770 | 16 Apr 2026 | Direct | ||
| Julie Rubinstein | ADPT | Common Stock | Sale | -4.42% | $278,467 | $14.61 | -19,060 | 412,498 | 15 Apr 2026 | Direct |
| Julie Rubinstein | ADPT | Common Stock | Options Exercise | 3.53% | 14,722 | 431,558 | 15 Apr 2026 | Direct | ||
| Julie Rubinstein | ADPT | Stock Option (right to buy) | Options Exercise | -8.26% | -14,722 | 163,492 | 15 Apr 2026 | Direct | ||
| Julie Rubinstein | ADPT | Common Stock | Sale | -4.37% | $277,514 | $14.56 | -19,060 | 416,836 | 14 Apr 2026 | Direct |
| Julie Rubinstein | ADPT | Common Stock | Options Exercise | 3.5% | 14,722 | 435,896 | 14 Apr 2026 | Direct | ||
| Julie Rubinstein | ADPT | Stock Option (right to buy) | Options Exercise | -7.63% | -14,722 | 178,214 | 14 Apr 2026 | Direct | ||
| Julie Rubinstein | ADPT | Common Stock | Sale | -4.33% | $250,599 | $13.15 | -19,060 | 421,174 | 13 Apr 2026 | Direct |
| Julie Rubinstein | ADPT | Common Stock | Options Exercise | 3.46% | 14,722 | 440,234 | 13 Apr 2026 | Direct | ||
| Julie Rubinstein | ADPT | Stock Option (right to buy) | Options Exercise | -100% | -14,722 | 0 | 13 Apr 2026 | Direct | ||
| Julie Rubinstein | ADPT | Common Stock | Sale | -4.29% | $243,307 | $12.77 | -19,060 | 425,512 | 10 Apr 2026 | Direct |
| Julie Rubinstein | ADPT | Common Stock | Options Exercise | 3.42% | 14,722 | 444,572 | 10 Apr 2026 | Direct | ||
| Julie Rubinstein | ADPT | Stock Option (right to buy) | Options Exercise | -64.5% | -14,722 | 8,109 | 10 Apr 2026 | Direct | ||
| Julie Rubinstein | ADPT | Common Stock | Sale | -4.25% | $264,202 | $13.86 | -19,060 | 429,850 | 09 Apr 2026 | Direct |
| Julie Rubinstein | ADPT | Common Stock | Options Exercise | 3.39% | 14,722 | 448,910 | 09 Apr 2026 | Direct | ||
| Julie Rubinstein | ADPT | Stock Option (right to buy) | Options Exercise | -39.2% | -14,722 | 22,831 | 09 Apr 2026 | Direct | ||
| Francis Lo | ADPT | Common Stock | Sale | -7.68% | $340,039 | $15.07 | -22,564 | 271,154 | 08 Apr 2026 | Direct |
| Francis Lo | ADPT | Common Stock | Options Exercise | 0.8% | 2,344 | 293,718 | 08 Apr 2026 | Direct | ||
| Francis Lo | ADPT | Stock Option (right to buy) | Options Exercise | -2.59% | -2,344 | 88,297 | 08 Apr 2026 | Direct | ||
| Harlan S. Robins | ADPT | Common Stock | Sale | -0.66% | $148,500 | $14.85 | -10,000 | 1,512,058 | 08 Apr 2026 | Direct |
| Chad M. Robins | ADPT | Common Stock | Sale | -1.68% | $566,025 | $15.19 | -37,263 | 2,180,518 | 08 Apr 2026 | Direct |
| Julie Rubinstein | ADPT | Common Stock | Sale | -6.65% | $458,920 | $14.83 | -30,941 | 434,188 | 08 Apr 2026 | Direct |
| Julie Rubinstein | ADPT | Common Stock | Options Exercise | 6.07% | 26,603 | 465,129 | 08 Apr 2026 | Direct | ||
| Julie Rubinstein | ADPT | Stock Option (right to buy) | Options Exercise | -41.5% | -26,603 | 37,553 | 08 Apr 2026 | Direct | ||
| Julie Rubinstein | ADPT | Common Stock | Sale | -4.17% | $258,454 | $13.56 | -19,060 | 438,526 | 07 Apr 2026 | Direct |
| Julie Rubinstein | ADPT | Common Stock | Options Exercise | 3.32% | 14,722 | 457,586 | 07 Apr 2026 | Direct | ||
| Julie Rubinstein | ADPT | Stock Option (right to buy) | Options Exercise | -22% | -14,722 | 52,275 | 07 Apr 2026 | Direct |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.